Pathogenesis of Trousseau’s syndrome

Abstract

Malignancies and thrombosis have common pathogenetic features that was shown by A. Trousseau in 1865. There is now no doubt that the cancer patients occur much more frequently thromboembolism, and migratory venous thrombosis is a manifestation of paraneoplastic syndrome in cancer patients. In general, any manifestation of thrombohemorrhagic complications in cancer patients called Trousseau’s syndrome. While thrombotic complications such as venous thromboembolism are most frequent in cancer patients, may also experience severe bleeding symptoms due to systemic coagulopathies, including disseminated intravascular coagulation, haemolytic thrombotic microangiopathy, and hyperfibrinolysis. The basis of the pathophysiology of Trousseau’s syndrome, except the classic triad of Virchow, is overproduction of tissue factor (TF), the main initiator of extrinsic coagulation pathway. Thus a significant release of microparticles from tumor cells bearing tissue factor is critical not only for the formation of a blood clot, but the growth and progression of tumors. Tumor cells activate the coagulation cascade or fibrinolysis system, providing conditions for its further spread, stimulation of angiogenesis, increased vascular permeability, which in turn promotes metastasis.

Keywords

Trousseau’s syndrome / malignancies, thrombotic complications / hemostasis system / metastasis of tumor tissue / DIC / thrombophilia / pathogenesis of thrombotic complications / cancer patients / prevention of thrombosis / hemostasis disorders

References

[1] Воробьев А. В. Состояние тромбоцитарного звена гемостаза у онкогинекологических больных. Материалы VI Российского форума «Мать и дитя». М.; 2004: 318-19.

[2] Макацария А. Д., Воробьев А. В., Бицадзе В. О. Злокачественные новообразования, тромбофилия, тромбозы. М.: Триада-Х; 2008.

[3] Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. М.: Медиа Сфера; 2010.

[4] Цыб А. Ф., Сушкевич Г. Н., Балуда М. В., Воробьев А. В., Чабров А. М. Принципы профилактики тромботических осложнений у онкологических больных (солидные образования). Пособие для врачей. Обнинск; 2008.

[5] Bharthuar A., Khorana A. A., Hutson A. et al. Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers. Thromb. Res. 2013; 132: 180-4.

[6] Chaturvedi S., Sidana S., Elson R., Khorana A. A., McCrae K. R. Symptomatic and incidental venousthromboembolic disease are both associated withmortality in patients with prostate cancer. PLoSOne. 2014; 9: e94048.

[7] Claussen C., Rausch A. V., Spath B. et al. Clinical significance of hemostatic activation markers inwomen with suspected ovarian cancer. Oncol. Res.Treat. 2014; 37: V669.

[8] Dammacco F., Vacca A., Procaccio P. et al. Cancer-related coagulopathy (Trousseau's syndrome): review of the literature and experience of a singlecenter of internal medicine. Clin. Exp. Med. 2013;13: 85-97.

[9] Davila M., Robles-Carrillo L., Unruh D. et al.Microparticle association and heterogeneity oftumor-derived tissue factor in plasma: is it important for coagulation activation? Thromb.Haemost. 2014; 12: 186-96.

[10] Demers M., Wagner D. D. NETosis: a new factor intumor progression and cancer-associated thrombosis. Semin.Thromb.Hemost. 2014; 40: 277-83.

[11] Fuchs T. A., Brill A., Wagner D. D. Neutrophil extracellular trap (NET) impact on deep vein thrombosis. Arterioscler. Thromb. Vase Biol. 2012; 32: 1777-83.

[12] Geddings J. E., Mackman N. Tumor-derived tissuefactor-positive microparticles and venous thrombosisincancer patients. Blood. 2013; 122: 1873-80.

[13] Hernandez C., Orbe J., Roncal C. et al. Tissue factorexpressed by microparticles is associated withmortality but not with thrombosis in cancer patients. Thromb. Haemost. 2013; 110: 598-608.

[14] Hyman D. M., Soff G. A., Kampel L. J. Disseminatedintravascular coagulation with excessive fibrinolysis in prostate cancer: a case series and review ofthe literature. Oncology. 2011; 81: 119-25.

[15] Khorana A. A. Risk assessment for cancer-associated thrombosis: what is the best approach? Thromb. Res. 2012; 129: S10-S15.

[16] Kitchens C. S. The contact system. Arch. Pathol. Lab. Med. 2002;126 (11): 1382-6.

[17] Kocatiirk B., Versteeg H. H. Tissue factor isoformsin cancer and coagulation: may the best isoformwin. Thromb. Res. 2012; 129: S69-S75.

[18] Langer F., Bokemeyer C. Crosstalk between cancerand haemostasis. Implications for cancer biologyand cancer-associated thrombosis with focus ontissue factor. Hamostaseologie. 2012; 32: 95-104.

[19] Lo L., Valentine H., Harrison J. et al. Tissue factorexpression in the metaplasia-adenoma-carcinomasequence of gastric cancer in a European population. Br. J. Cancer. 2012; 107: 1125-30.

[20] Mackman N. New insights into the mechanisms ofvenous thrombosis. J Clin Invest 2012; 122: 2331-6.

[21] Rak J., Yu J. L., Luyendyk J., Mackman N. Oncogenes, trousseau syndrome, and cancer-related changesin the coagulome of mice and humans. Cancer Res. 2006; 66: 10643-6.

[22] Thaler I., Ay C., Mackman N. et al. Microparticle-associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathologicalfeatures. Eur. J. Clin. Invest. 2013; 43: 277-85.

[23] Thaler J., Preusser M., Ay C. et al. Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients. Thromb. Res. 2013; 131: 162-5.

[24] Trousseau A. Phlegmasia alba dolens. Clinique Medicale de l'Hotel-Dieu de Paris. 1865; 3: 654-712.

[25] Van Doormaal F. K., Terpstra W., Van Der Griend R. et al. Is extensive screening for cancer in idiopathicvenous thromboembolism warranted? J. Thromb.Haemost. 2011; 9: 79-84.

[26] Varki A. Trousseaus syndrome: multiple definitions and multiple mechanisms. Blood. 2007; 110: 1723-9.

[27] Vorobiev A. V., Makatsaria A. D., Chabrov A. M. Thrombophilia markers in cancer patients during chemotherapy and radiation therapy. Pathophysiology of haemostasis and thrombosis 2006; 35 (1-2): A20.

RIGHTS & PERMISSIONS

Vorobev A.V., Makatsaria A.D., Chabrov A.M., Savchenko A.A.